Abstract
Neurodegenerative diseases, such as Alzheimer's disease (AD), are expensive, common, and will likely increase as the population ages. The lack of significant therapeutic development indicates that further research is needed on various cellular mechanisms that contribute to neurodegeneration. Human-induced pluripotent stem cell (hiPSC) technology has provided living, dynamic cellular models to address this challenge. Here, we discuss these models in the context of AD and related dementias and review the insights these models have made into disease mechanisms. We include discussion of genetic forms of AD and strong AD risk factors and discuss how these are modeled in both two-dimensional cultures and three-dimensional cerebral organoids. We address the limitations of the system, in particular how to incorporate brain aging, and we summarize drug discovery efforts using hiPSC-derived neurons.
| Original language | English |
|---|---|
| Title of host publication | Phenotyping of Human iPSC-derived Neurons |
| Subtitle of host publication | Patient-Driven Research |
| Editors | Elizabeth D. Buttermore |
| Publisher | Elsevier |
| Chapter | 11 |
| Pages | 243-261 |
| Number of pages | 19 |
| ISBN (Electronic) | 9780128222775 |
| ISBN (Print) | 9780128222782 |
| DOIs | |
| Publication status | Published - 2023 |
Bibliographical note
Publisher Copyright:© 2023 Elsevier Inc. All rights reserved.
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
Keywords
- 3D model challenges
- Age-related disorders
- Alzheimer's disease
- Apolipoprotein E
- Cerebral organoids
- Drug discovery
- Familial Alzheimer's disease
- Induced pluripotent stem cells
- iPSCs
- Organoids
- Progerin
- Sporadic Alzheimer's disease
- Tauopathies
Fingerprint
Dive into the research topics of 'Advantages and limitations of hiPSC-derived neurons for the study of neurodegeneration'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver